Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1994-6-30
|
| pubmed:abstractText |
The management of locally advanced breast cancer with single modality therapy has been associated with a high rate of systemic failure. A multimodality treatment strategy that includes induction cytotoxic chemotherapy, surgery, radiation therapy, and, possibly, hormonal ablation therapy is the current preferred management approach. As our knowledge and understanding of the mechanisms involved in mitogenic signal transduction improve, it is likely that less toxic, more efficacious agents will emerge.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0364-2313
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
81-6
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8197781-Antineoplastic Agents,
pubmed-meshheading:8197781-Breast Neoplasms,
pubmed-meshheading:8197781-Clinical Trials as Topic,
pubmed-meshheading:8197781-Combined Modality Therapy,
pubmed-meshheading:8197781-Female,
pubmed-meshheading:8197781-Humans,
pubmed-meshheading:8197781-Randomized Controlled Trials as Topic
|
| pubmed:articleTitle |
Management of locally advanced breast cancer.
|
| pubmed:affiliation |
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
|
| pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|